Brief: Fluidigm Confirms Advanta Dx SARS-Cov-2 RT-PCR Assay On The Company’s Biomark Platform Detects Omicron Variant Of Covid-19

Standard BioTools

07/12/2021 13:36

Dec 7 (Reuters) - Fluidigm Corp  FLDM.O :
    * FLUIDIGM CONFIRMS ADVANTA DX SARS-COV-2 RT-PCR ASSAY ON
THE
COMPANY’S BIOMARK PLATFORM DETECTS OMICRON VARIANT OF COVID-19

Source text for Eikon:  ID:nGNX3y40DS 
Further company coverage:  FLDM.O 

 ((Reuters.Briefs@thomsonreuters.com;))